Defending Eat Out to Help Out – PM's day at Covid inquiry
Arriving amongst protests, Rishi Sunak defends his time as chancellor during the pandemic, as he gives evidence to the Covid inquiry.
Similar Posts
Whooping cough cases in Wales show sharp increase
Cases of whooping cough are rising rapidly in Wales for the first time in five years.
King Charles III to be treated for prostate condition, know the signs and symptoms of the cancer found in men
Prostate cancer is the most common cancer found in men. King Charles III is one public figure who has been open about his prostate procedure. Buckingham Palace announced that the king would receive hospital treatment for an enlarged prostate, a condition also very common in men. KING CHARLES II TO UNDERGO ‘CORRECTIVE PROCEDURE’ NEXT WEEK…
JN.1 variant no more severe than other COVID-19 strains, CDC says
Join Fox News for access to this content Plus get unlimited access to thousands of articles, videos and more with your free account! Please enter a valid email address. By entering your email, you are agreeing to Fox News Terms of Service and Privacy Policy, which includes our Notice of Financial Incentive. To access the…
Singapore urges public to continue getting vaccinated as cases surge
SINGAPORE — Singapore’s latest spike in Covid cases may be starting to peak — but the public needs to stay up to date on vaccinations, Health Minister Ong Ye Kung told CNBC on Thursday. Singapore reported 56,043 Covid cases in the week of Dec. 3 to 9, marking a 75% surge compared to the week…
Humana reports grim 2024 forecast due to soaring medical costs
Signage is displayed on a Humana Inc. office building in Louisville, Kentucky, U.S., on Sunday, Feb. 3, 2019. Humana is scheduled to release earnings figures on February 6. Photographer: Luke Sharrett/Bloomberg via Getty Images Bloomberg | Bloomberg | Getty Images Shares of Humana plummeted on Thursday after the health insurer issued dismal full-year earnings guidance,…
Gilead stock falls after lung cancer study results disappoint
Sopa Images | Lightrocket | Getty Images Shares of Gilead fell more than 10% on Monday after a key drug from the company did not significantly extend the lives of patients with a certain lung cancer in a late-stage trial. The results are a blow to Gilead, which is working to become a power player…